Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

By Keunchil Park, E. Tan, K. O'Byrne, Li Zhang, M. Boyer, T. Mok, V. Hirsh, Jie Yang, K. Lee, Shun Lu and 13 more. The Lancet Oncology, 2016

1,055 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/1e54cc9c7b76b2ad1a90e9ff708082b354389d9a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. K. Kerr
2. M. Hellmann

Citations in the corpus

• Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018, background): “Regimen Osimertinib (n=279) Standard EGFR-TKI (n=277) First post-treatment anticancer therapy (including cross-over osimertinib), n (%) Discontinued randomized trial treatment 138 (49) 213 (77) First post-treatment anticancer therapy 82 (29) 129 (47) No post-treatment anticancer therapy 56 (20) 84 (”
• Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, background): “LUX-Lung 7 is a randomised phase IIB study that compares afatinib with gefitinib [181].”